Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Long-Term Investments (2016 - 2023)

Historic Long-Term Investments for ImmunityBio (IBRX) over the last 10 years, with Q4 2023 value amounting to $891000.0.

  • ImmunityBio's Long-Term Investments rose 607.14% to $891000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $891000.0, marking a year-over-year increase of 607.14%. This contributed to the annual value of $891000.0 for FY2023, which is 607.14% up from last year.
  • According to the latest figures from Q4 2023, ImmunityBio's Long-Term Investments is $891000.0, which was up 607.14% from $817000.0 recorded in Q3 2023.
  • In the past 5 years, ImmunityBio's Long-Term Investments registered a high of $9.3 million during Q2 2020, and its lowest value of $802000.0 during Q3 2021.
  • For the 5-year period, ImmunityBio's Long-Term Investments averaged around $4.1 million, with its median value being $902500.0 (2022).
  • As far as peak fluctuations go, ImmunityBio's Long-Term Investments crashed by 9137.63% in 2021, and later skyrocketed by 1119.22% in 2022.
  • Quarter analysis of 5 years shows ImmunityBio's Long-Term Investments stood at $9.3 million in 2019, then decreased by 15.17% to $7.8 million in 2020, then plummeted by 89.53% to $822000.0 in 2021, then grew by 2.19% to $840000.0 in 2022, then grew by 6.07% to $891000.0 in 2023.
  • Its Long-Term Investments stands at $891000.0 for Q4 2023, versus $817000.0 for Q3 2023 and $841000.0 for Q2 2023.